Former Alphabet employees told STAT that their tech expertise could come in handy for health systems trying to get up to speed on data.January 31, 2023Check out STAT+Sponsored By Sean Gallup/Getty Images STAT+ | Alphabet's laid-off health tech employees on where their work heads next Former Alphabet employees swept up in recent layoffs said tech expertise could help health systems trying to get up to speed on data. By Brittany Trang STAT+ | Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients "Warped incentives baked into the U.S. drug channel will limit savings from biosimilars," said Adam Fein of the Drug Channels Institute. By Ed Silverman Opinion: A watershed year for biosimilars — if regulators and policymakers step up 2023 could be a banner year for biosimilars if regulators and policymakers require them to be included in Medicare and other formularies. By Juliana M. Reed Andrew Harnik/AP Town Hall Ventures' Andy Slavitt on how to invest in Medicaid and health tech Part of Andy Slavitt's mission at Town Hall Ventures is proving that health tech companies can make a viable business working in Medicaid. By Mohana Ravindranath Opinion: How the Biden administration's Covid preparedness policies could narrow America's political divide The White House's Covid Winter Preparedness plan sidesteps the emerging evidence base and President Biden's pledge to "follow the science." By Steven Phillips and Robert C. Gallo and Christian Bréchot More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments